This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to cause a low lymphocyte (white blood cell) count in the blood, which may help the infused BCMA CAR-T cells survive and expand.
Cyclophosphamide is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It can be given as a pill, a liquid, or as an injection into a vein through an IV.
The following criteria is provided for health care professionals.
Call us at (888) 828-2206 and we can answer any questions and help get you connected with this study team.
Our system will analyze your profile against hundreds of clinical trials to find ones that may be right for you.
This center is currently accepting patients.
This trial is currently open and accepting patients.
25 sparks required
Weekdays 9am - 5pm EST
Create your account today and we can alert you when this trial opens recruitment.
Or call us today, and we can help answer any questions that you may have.